Cancer Research Meeting Calendar Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 1626-1634, April 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tozer, G. M.
Right arrow Articles by Chaplin, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tozer, G. M.
Right arrow Articles by Chaplin, D. J.
[Cancer Research 59, 1626-1634, April 1, 1999]
© 1999 American Association for Cancer Research

Tumor Biology

Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent

Early Effects in Tumors and Normal Tissues1

Gillian M. Tozer2, Vivien E. Prise, John Wilson, Rosalind J. Locke, Borivoj Vojnovic, Michael R. L. Stratford, Madeleine F. Dennis and David J. Chaplin

Tumor Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, United Kingdom

The potential for tumor vascular-targeting by using the tubulin destabilizing agent disodium combretastatin A-4 3-0-phosphate (CA-4-P) was assessed in a rat system. This approach aims to shut down the established tumor vasculature, leading to the development of extensive tumor cell necrosis. The early vascular effects of CA-4-P were assessed in the s.c. implanted P22 carcinosarcoma and in a range of normal tissues. Blood flow was measured by the uptake of radiolabeled iodoantipyrine, and quantitative autoradiography was used to measure spatial heterogeneity of blood flow in tumor sections. CA-4-P (100 mg/kg i.p.) caused a significant increase in mean arterial blood pressure at 1 and 6 h after treatment and a very large decrease in tumor blood flow, which—by 6 h—was reduced approximately 100-fold. The spleen was the most affected normal tissue with a 7-fold reduction in blood flow at 6 h. Calculations of vascular resistance revealed some vascular changes in the heart and kidney for which there were no significant changes in blood flow. Quantitative autoradiography showed that CA-4-P increased the spatial heterogeneity in tumor blood flow. The drug affected peripheral tumor regions less than central regions. Administration of CA-4-P (30 mg/kg) in the presence of the nitric oxide synthase inhibitor, N{omega}-nitro-L-arginine methyl ester, potentiated the effect of CA-4-P in tumor tissue. The combination increased tumor vascular resistance 300-fold compared with less than 7-fold for any of the normal tissues. This shows that tissue production of nitric oxide protects against the damaging vascular effects of CA-4-P. Significant changes in tumor vascular resistance could also be obtained in isolated tumor perfusions using a cell-free perfusate, although the changes were much less than those observed in vivo. This shows that the action of CA-4-P includes mechanisms other than those involving red cell viscosity, intravascular coagulation, and neutrophil adhesion. The uptake of CA-4-P and combretastatin A-4 (CA-4) was more efficient in tumor than in skeletal muscle tissue and dephosphorylation of CA-4-P to CA-4 was faster in the former. These results are promising for the use of CA-4-P as a tumor vascular-targeting agent.




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
H. Quan, H. Liu, C. Li, and L. Lou
1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) Enhances the Cytotoxicity of Combretastatin A4 Independently of Mitogen-Activated Protein Kinase Kinase
J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 326 - 333.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. M. Tozer, V. E. Prise, G. Lewis, S. Xie, I. Wilson, and S. A. Hill
Nitric Oxide Synthase Inhibition Enhances the Tumor Vascular-Damaging Effects of Combretastatin A-4 3-O-Phosphate at Clinically Relevant Doses
Clin. Cancer Res., June 1, 2009; 15(11): 3781 - 3790.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli, A. Rossi, P. Maione, E. Rossi, V. Castaldo, P. C. Sacco, and G. Colantuoni
Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle Against Non-Small Cell Lung Cancer
Oncologist, June 1, 2009; 14(6): 612 - 620.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
W. W. Ma and A. A. Adjei
Novel Agents on the Horizon for Cancer Therapy
CA Cancer J Clin, March 1, 2009; 59(2): 111 - 137.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
G M Tozer, C Kanthou, G Lewis, V E Prise, B Vojnovic, and S A Hill
Tumour vascular disrupting agents: combating treatment resistance
Br. J. Radiol., October 1, 2008; 81(Special_Issue_1): S12 - S20.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
D. Zhao, E. Richer, P. P. Antich, and R. P. Mason
Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI
FASEB J, July 1, 2008; 22(7): 2445 - 2451.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Aprile, E. Del Grosso, G. C. Tron, and G. Grosa
In Vitro Metabolism Study of Combretastatin A-4 in Rat and Human Liver Microsomes
Drug Metab. Dispos., December 1, 2007; 35(12): 2252 - 2261.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. J. Kim, M. Ravoori, C. N. Landen, A. A. Kamat, L. Y. Han, C. Lu, Y. G. Lin, W. M. Merritt, N. Jennings, W. A. Spannuth, et al.
Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma
Cancer Res., October 1, 2007; 67(19): 9337 - 9345.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H.-L. Lin, S.-H. Chiou, C.-W. Wu, W.-B. Lin, L.-H. Chen, Y.-P. Yang, M.-L. Tsai, Y.-H. Uen, J.-P. Liou, and C.-W. Chi
Combretastatin A4-Induced Differential Cytotoxicity and Reduced Metastatic Ability by Inhibition of AKT Function in Human Gastric Cancer Cells
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Horsman and D. W. Siemann
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
Cancer Res., December 15, 2006; 66(24): 11520 - 11539.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Kanthou, S. Kranjc, G. Sersa, G. Tozer, A. Zupanic, and M. Cemazar
The endothelial cytoskeleton as a target of electroporation-based therapies
Mol. Cancer Ther., December 1, 2006; 5(12): 3145 - 3152.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Badn, S. Kalliomaki, B. Widegren, and H. O. Sjogren
Low-Dose Combretastatin A4 Phosphate Enhances the Immune Response of Tumor Hosts to Experimental Colon Carcinoma
Clin. Cancer Res., August 1, 2006; 12(15): 4714 - 4719.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
H. C. Thoeny, F. De Keyzer, V. Vandecaveye, F. Chen, X. Sun, H. Bosmans, R. Hermans, E. K. Verbeken, C. Boesch, G. Marchal, et al.
Effect of Vascular Targeting Agent in Rat Tumor Model: Dynamic Contrast-enhanced versus Diffusion-weighted MR Imaging
Radiology, November 1, 2005; 237(2): 492 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Dong, B. Ko, P. Baumeister, S. Swenson, F. Costa, F. Markland, C. Stiles, J. B. Patterson, S. E. Bates, and A. S. Lee
Vascular Targeting and Antiangiogenesis Agents Induce Drug Resistance Effector GRP78 within the Tumor Microenvironment
Cancer Res., July 1, 2005; 65(13): 5785 - 5791.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Belleri, D. Ribatti, S. Nicoli, F. Cotelli, L. Forti, V. Vannini, L. A. Stivala, and M. Presta
Antiangiogenic and Vascular-Targeting Activity of the Microtubule-Destabilizing trans-Resveratrol Derivative 3,5,4'-Trimethoxystilbene
Mol. Pharmacol., May 1, 2005; 67(5): 1451 - 1459.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
H. C. Thoeny, F. De Keyzer, F. Chen, Y. Ni, W. Landuyt, E. K. Verbeken, H. Bosmans, G. Marchal, and R. Hermans
Diffusion-weighted MR Imaging in Monitoring the Effect of a Vascular Targeting Agent on Rhabdomyosarcoma in Rats
Radiology, March 1, 2005; 234(3): 756 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. R. Wachsberger, R. Burd, N. Marero, C. Daskalakis, A. Ryan, P. McCue, and A. P. Dicker
Effect of the Tumor Vascular-Damaging Agent, ZD6126, on the Radioresponse of U87 Glioblastoma
Clin. Cancer Res., January 15, 2005; 11(2): 835 - 842.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. Escalona-Benz, M.-E. Jockovich, T. G. Murray, B. Hayden, E. Hernandez, W. Feuer, and J. J. Windle
Combretastatin A-4 Prodrug in the Treatment of a Murine Model of Retinoblastoma
Invest. Ophthalmol. Vis. Sci., January 1, 2005; 46(1): 8 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Kanthou, O. Greco, A. Stratford, I. Cook, R. Knight, O. Benzakour, and G. Tozer
The Tubulin-Binding Agent Combretastatin A-4-Phosphate Arrests Endothelial Cells in Mitosis and Induces Mitotic Cell Death
Am. J. Pathol., October 1, 2004; 165(4): 1401 - 1411.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. E. Thorpe
Vascular Targeting Agents as Cancer Therapeutics
Clin. Cancer Res., January 15, 2004; 10(2): 415 - 427.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Stevenson, M. Rosen, W. Sun, M. Gallagher, D. G. Haller, D. Vaughn, B. Giantonio, R. Zimmer, W. P. Petros, M. Stratford, et al.
Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow
J. Clin. Oncol., December 1, 2003; 21(23): 4428 - 4438.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
G M Tozer
Measuring tumour vascular response to antivascular and antiangiogenic drugs
Br. J. Radiol., December 1, 2003; 76(suppl_1): S23 - S35.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
S M Galbraith
Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development
Br. J. Radiol., December 1, 2003; 76(suppl_1): S83 - S86.
[Full Text] [PDF]

Home page
 IOVSHome page
H. Nambu, R. Nambu, M. Melia, and P. A. Campochiaro
Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization
Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3650 - 3655.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Collins
Functional Imaging in Phase I Studies: Decorations or Decision Making?
J. Clin. Oncol., August 1, 2003; 21(15): 2807 - 2809.
[Full Text] [PDF]

Home page
 JCOHome page
G. J.S. Rustin, S. M. Galbraith, H. Anderson, M. Stratford, L. K. Folkes, L. Sena, L. Gumbrell, and P. M. Price
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
J. Clin. Oncol., August 1, 2003; 21(15): 2815 - 2822.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. L. Anderson, J. T. Yap, M. P. Miller, A. Robbins, T. Jones, and P. M. Price
Assessment of Pharmacodynamic Vascular Response in a Phase I Trial of Combretastatin A4 Phosphate
J. Clin. Oncol., August 1, 2003; 21(15): 2823 - 2830.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Galbraith, R. J. Maxwell, M. A. Lodge, G. M. Tozer, J. Wilson, N. J. Taylor, J. J. Stirling, L. Sena, A. R. Padhani, and G. J.S. Rustin
Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging
J. Clin. Oncol., August 1, 2003; 21(15): 2831 - 2842.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Wachsberger, R. Burd, and A. P. Dicker
Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction
Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. D. Davis, G. J. Dougherty, D. C. Blakey, S. M. Galbraith, G. M. Tozer, A. L. Holder, M. A. Naylor, J. Nolan, M. R. L. Stratford, D. J. Chaplin, et al.
ZD6126: A Novel Vascular-targeting Agent That Causes Selective Destruction of Tumor Vasculature
Cancer Res., December 15, 2002; 62(24): 7247 - 7253.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. M. Seddon, R. J. Maxwell, D. J. Honess, R. Grimshaw, F. Raynaud, G. M. Tozer, and P. Workman
Validation of the Fluorinated 2-Nitroimidazole SR-4554 as a Noninvasive Hypoxia Marker Detected by Magnetic Resonance Spectroscopy
Clin. Cancer Res., July 1, 2002; 8(7): 2323 - 2335.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Dowlati, K. Robertson, M. Cooney, W. P. Petros, M. Stratford, J. Jesberger, N. Rafie, B. Overmoyer, V. Makkar, B. Stambler, et al.
A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer
Cancer Res., June 1, 2002; 62(12): 3408 - 3416.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. C. Blakey, F. R. Westwood, M. Walker, G. D. Hughes, P. D. Davis, S. E. Ashton, and A. J. Ryan
Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models
Clin. Cancer Res., June 1, 2002; 8(6): 1974 - 1983.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Kanthou and G. M. Tozer
The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells
Blood, March 15, 2002; 99(6): 2060 - 2069.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Griggs, J. N. Skepper, G. A. Smith, K. M. Brindle, J. C. Metcalfe, and R. Hesketh
Inhibition of Proliferative Retinopathy by the Anti-Vascular Agent Combretastatin-A4
Am. J. Pathol., March 1, 2002; 160(3): 1097 - 1103.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. M. Tozer, V. E. Prise, J. Wilson, M. Cemazar, S. Shan, M. W. Dewhirst, P. R. Barber, B. Vojnovic, and D. J. Chaplin
Mechanisms Associated with Tumor Vascular Shut-Down Induced by Combretastatin A-4 Phosphate: Intravital Microscopy and Measurement of Vascular Permeability
Cancer Res., September 1, 2001; 61(17): 6413 - 6422.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. A. Beauregard, S. A. Hill, D. J. Chaplin, and K. M. Brindle
The Susceptibility of Tumors to the Antivascular Drug Combretastatin A4 Phosphate Correlates with Vascular Permeability
Cancer Res., September 1, 2001; 61(18): 6811 - 6815.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Pedley, S. A. Hill, G. M. Boxer, A. A. Flynn, R. Boden, R. Watson, J. Dearling, D. J. Chaplin, and R. H. J. Begent
Eradication of Colorectal Xenografts by Combined Radioimmunotherapy and Combretastatin A-4 3-O-Phosphate
Cancer Res., June 1, 2001; 61(12): 4716 - 4722.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. S. Boehle, B. Sipos, U. Kliche, H. Kalthoff, and P. Dohrmann
Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model
Ann. Thorac. Surg., May 1, 2001; 71(5): 1657 - 1665.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Gee, H. M. Saunders, J. C. Lee, J. F. Sanzo, W. T. Jenkins, S. M. Evans, G. Trinchieri, C. M. Sehgal, M. D. Feldman, and W. M. F. Lee
Doppler Ultrasound Imaging Detects Changes in Tumor Perfusion during Antivascular Therapy Associated with Vascular Anatomic Alterations
Cancer Res., April 1, 2001; 61(7): 2974 - 2982.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
C. Malcontenti-Wilson, V. Muralidharan, S. Skinner, C. Christophi, D. Sherris, and P. E. O’Brien
Combretastatin A4 Prodrug Study of Effect on the Growth and the Microvasculature of Colorectal Liver Metastases in a Murine Model
Clin. Cancer Res., April 1, 2001; 7(4): 1052 - 1060.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
B. G. Siim, W. T. Laux, M. D. Rutland, B. N. Palmer, and W. R. Wilson
Scintigraphic Imaging of the Hypoxia Marker 99mTechnetium-labeled 2,2'-(1,4-Diaminobutane)bis(2-methyl-3-butanone) Dioxime (99mTc-labeled HL-91; Prognox): Noninvasive Detection of Tumor Response to the Antivascular Agent 5,6-Dimethylxanthenone-4-acetic Acid
Cancer Res., August 1, 2000; 60(16): 4582 - 4588.
[Abstract] [Full Text]

Home page
 FASEB J.Home page
Y. GUO, A. A.-R. HIGAZI, A. ARAKELIAN, B. S. SACHAIS, D. CINES, R. H. GOLDFARB, T. R. JONES, H. KWAAN, A. P. MAZAR, and S. A. RABBANI
A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo
FASEB J, July 1, 2000; 14(10): 1400 - 1410.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
Y. S. Lew, S. L. Brown, R. J. Griffin, C. W. Song, and J. H. Kim
Arsenic Trioxide Causes Selective Necrosis in Solid Murine Tumors by Vascular Shutdown
Cancer Res., December 1, 1999; 59(24): 6033 - 6037.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.